drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting cadherin‑17 (CDH17). CAR engagement triggers CD3ζ/costimulatory signaling, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CDH17-positive tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a chimeric antigen receptor targeting CDH17. Upon CDH17 binding, the CAR delivers CD3-zeta and costimulatory signals that activate and expand T cells, leading to cytokine release and perforin/granzyme-mediated cytotoxic killing of CDH17-positive tumor cells.
drug_name
CDH17 CAR-T (UCLH801)
nct_id_drug_ref
NCT06937567